143 related articles for article (PubMed ID: 37458549)
41. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
42. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
Ali S; Olszewski AJ
Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
[TBL] [Abstract][Full Text] [Related]
43. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Eichenauer DA; Fuchs M
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
[TBL] [Abstract][Full Text] [Related]
44. Modern management of lymphocyte-predominant Hodgkin lymphoma.
Xing KH; Savage KJ
Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
[TBL] [Abstract][Full Text] [Related]
45. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.
Shankar A; Daw S
Br J Haematol; 2012 Nov; 159(3):288-98. PubMed ID: 22994199
[TBL] [Abstract][Full Text] [Related]
46. Hodgkin lymphoma.
Connors JM; Cozen W; Steidl C; Carbone A; Hoppe RT; Flechtner HH; Bartlett NL
Nat Rev Dis Primers; 2020 Jul; 6(1):61. PubMed ID: 32703953
[TBL] [Abstract][Full Text] [Related]
47. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Hartmann S; Eichenauer DA; Plütschow A; Mottok A; Bob R; Koch K; Bernd HW; Cogliatti S; Hummel M; Feller AC; Ott G; Möller P; Rosenwald A; Stein H; Hansmann ML; Engert A; Klapper W
Blood; 2013 Dec; 122(26):4246-52; quiz 4292. PubMed ID: 24100447
[TBL] [Abstract][Full Text] [Related]
48. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
49. SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.
Rueda Domínguez A; Alfaro Lizaso J; de la Cruz Merino L; Gumá I Padró J; Quero Blanco C; Gómez Codina J; Llanos Muñoz M; Martinez Banaclocha N; Rodriguez Abreu D; Provencio Pulla M
Clin Transl Oncol; 2015 Dec; 17(12):1005-13. PubMed ID: 26497354
[TBL] [Abstract][Full Text] [Related]
50. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
Andersen MD; Hamilton-Dutoit S; Modvig L; Vase M; Christiansen I; Christensen JH; Dahl-Sørensen RB; Stoltenberg D; Kamper P; d'Amore F
Br J Haematol; 2022 Jul; 198(1):50-61. PubMed ID: 35396711
[TBL] [Abstract][Full Text] [Related]
51. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
52. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
53. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
54. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
Barber NA; Loberiza FR; Perry AM; Bast M; Holdeman KP; Esfahane AB; Weisenburger DD; Vose J; Bierman P; Armitage JO; Bociek RG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
[TBL] [Abstract][Full Text] [Related]
55. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
56. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
Sioka C
Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
[TBL] [Abstract][Full Text] [Related]
57. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
58. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.
Hutchings M; Loft A; Hansen M; Ralfkiaer E; Specht L
Hematol Oncol; 2006 Sep; 24(3):146-50. PubMed ID: 16729353
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
